The post Ripple Presses SEC to End ‘Forever Securities’ Problem in Crypto as Congress Debates Clarity Act appeared first on Coinpedia Fintech News Ripple has submittedThe post Ripple Presses SEC to End ‘Forever Securities’ Problem in Crypto as Congress Debates Clarity Act appeared first on Coinpedia Fintech News Ripple has submitted

Ripple Presses SEC to End ‘Forever Securities’ Problem in Crypto as Congress Debates Clarity Act

XRP Lawsuit

The post Ripple Presses SEC to End ‘Forever Securities’ Problem in Crypto as Congress Debates Clarity Act appeared first on Coinpedia Fintech News

Ripple has submitted a detailed letter to the U.S. Securities and Exchange Commission’s Crypto Task Force, calling for a clearer and more practical approach to regulating digital assets. The letter, dated January 9, 2026, argues that current regulatory thinking creates confusion by failing to separate a crypto asset from the contract under which it was originally sold.

Ripple said future crypto rules should be based on legal rights and enforceable obligations, not vague concepts that change over time.

Ripple strongly criticized the use of “decentralization” as a regulatory standard, calling it subjective and unreliable. The company said decentralization is not a fixed condition and can vary based on governance, code development, economics, and network participation.

According to Ripple, relying on decentralization risks two outcomes: allowing risky assets to escape oversight or trapping mature assets under securities laws long after they no longer function like securities.

Promises matter, not price hopes

Ripple warned against reducing securities analysis to whether buyers expect profits from the “efforts of others.” It said securities laws exist to regulate enforceable promises, not investor optimism.

If no legal promise exists, Ripple argued, buying a digital asset in hopes of price appreciation is a market risk — not a securities transaction. Once a company’s original obligations are fulfilled or expire, the asset itself should no longer fall under securities regulation.

Secondary market trades should not be securities

A major focus of the letter was secondary market trading. Ripple said that once an asset trades freely on exchanges, without a direct relationship between buyer and issuer, securities laws should not apply.

The company compared crypto markets to commodities like gold or silver, which trade actively but are not considered securities. Ripple said high trading volume does not change an asset’s legal nature.

Ripple emphasized the importance of privity, meaning a direct relationship between buyer and issuer. In primary sales, such as initial offerings, privity exists and securities rules may apply.

In mature markets, however, buyers and sellers transact anonymously, with no direct contract or promise from the issuer. Ripple argued that treating every later sale as a capital raise would create endless legal obligations and paralyze normal business activity.

Control should be defined clearly

Ripple acknowledged that regulation may still apply if a company retains direct control over a network or token, such as the ability to change code or reverse transactions. However, it stressed that control must be objectively defined.

Holding tokens, participating in open governance, or sharing economic interests should not automatically count as control, the company said.

Aligns with SEC leadership views

Ripple said that its position aligns with remarks by SEC Chairman Paul Atkins, who said investment contracts describe relationships between parties, not permanent labels attached to assets. Once promises end, regulatory obligations should end as well.

The company said clear, rights-based regulation would protect investors, reduce confusion, and allow U.S. crypto markets to mature without unnecessary legal uncertainty.

Market Opportunity
The AI Prophecy Logo
The AI Prophecy Price(ACT)
$0.02602
$0.02602$0.02602
-0.98%
USD
The AI Prophecy (ACT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23